Tags

Type your tag names separated by a space and hit enter

[Serum bone marker measurements in bone metabolism disorders associated with inflammatory bowel diseases].
Orv Hetil 2001; 142(29):1557-60OH

Abstract

Patients with inflammatory bowel disease (IBD) have decreased bone mineral density (BMD), which is usually much more remarkable in patients with Crohn's disease (CD) than those with ulcerative colitis (UC). The aim of the present study was to investigate the usefulness of serum beta-Crosslaps (bCL) and osteocalcin (OC) determinations to assess bone metabolism in patients with IBD. Forty-nine patients with IBD (23 UC, 26 CD) and 46 healthy controls were studied. Serum bCL and OC were measured by Elecsys immunoassay. Compared to controls (0.275 +/- 0.14 ng/ml) the mean bCL concentration was significantly higher in the CD (mean = 0.489 +/- 0.25 ng/ml; p < 0.001) and UC groups (mean = 0.439 +/- 0.3 ng/ml; p < 0.01). The mean OC concentration was significantly higher in the CD group (28.52 +/- 14.75 ng/ml) than in controls (21.42 +/- 7.43 ng/ml) but OC level was not significantly increased in the UC group (24.89 +/- 15.08 ng/ml). There was no significant difference in bCL or OC concentrations between the CD and UC groups. These results indicate that the accelerated bone resorption is not associated with increased bone formation in patients with IBD. These two marker of the bone metabolism could be a good laboratory parameter of bone pathology in patients with IBD, especially in CD.

Authors+Show Affiliations

Altalános Orvostudományi Kar, II. Belgyógyászati Klinika, Semmelweis Egyetem, Budapest.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article

Language

hun

PubMed ID

11494747

Citation

Miheller, P, et al. "[Serum Bone Marker Measurements in Bone Metabolism Disorders Associated With Inflammatory Bowel Diseases]." Orvosi Hetilap, vol. 142, no. 29, 2001, pp. 1557-60.
Miheller P, Tóth M, Molnár E, et al. [Serum bone marker measurements in bone metabolism disorders associated with inflammatory bowel diseases]. Orv Hetil. 2001;142(29):1557-60.
Miheller, P., Tóth, M., Molnár, E., Zágoni, T., Rácz, K., & Tulassay, Z. (2001). [Serum bone marker measurements in bone metabolism disorders associated with inflammatory bowel diseases]. Orvosi Hetilap, 142(29), pp. 1557-60.
Miheller P, et al. [Serum Bone Marker Measurements in Bone Metabolism Disorders Associated With Inflammatory Bowel Diseases]. Orv Hetil. 2001 Jul 22;142(29):1557-60. PubMed PMID: 11494747.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Serum bone marker measurements in bone metabolism disorders associated with inflammatory bowel diseases]. AU - Miheller,P, AU - Tóth,M, AU - Molnár,E, AU - Zágoni,T, AU - Rácz,K, AU - Tulassay,Z, PY - 2001/8/10/pubmed PY - 2002/3/14/medline PY - 2001/8/10/entrez SP - 1557 EP - 60 JF - Orvosi hetilap JO - Orv Hetil VL - 142 IS - 29 N2 - Patients with inflammatory bowel disease (IBD) have decreased bone mineral density (BMD), which is usually much more remarkable in patients with Crohn's disease (CD) than those with ulcerative colitis (UC). The aim of the present study was to investigate the usefulness of serum beta-Crosslaps (bCL) and osteocalcin (OC) determinations to assess bone metabolism in patients with IBD. Forty-nine patients with IBD (23 UC, 26 CD) and 46 healthy controls were studied. Serum bCL and OC were measured by Elecsys immunoassay. Compared to controls (0.275 +/- 0.14 ng/ml) the mean bCL concentration was significantly higher in the CD (mean = 0.489 +/- 0.25 ng/ml; p < 0.001) and UC groups (mean = 0.439 +/- 0.3 ng/ml; p < 0.01). The mean OC concentration was significantly higher in the CD group (28.52 +/- 14.75 ng/ml) than in controls (21.42 +/- 7.43 ng/ml) but OC level was not significantly increased in the UC group (24.89 +/- 15.08 ng/ml). There was no significant difference in bCL or OC concentrations between the CD and UC groups. These results indicate that the accelerated bone resorption is not associated with increased bone formation in patients with IBD. These two marker of the bone metabolism could be a good laboratory parameter of bone pathology in patients with IBD, especially in CD. SN - 0030-6002 UR - https://www.unboundmedicine.com/medline/citation/11494747/[Serum_bone_marker_measurements_in_bone_metabolism_disorders_associated_with_inflammatory_bowel_diseases]_ DB - PRIME DP - Unbound Medicine ER -